# psoriasis - deepseek-v4-flash

- Benchmark system: raw
- Repeat: 4
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 3982
- Completion tokens: 27716
- Reasoning tokens: 
- Total tokens: 31698
- API requests reported: 
- Elapsed seconds: 259.509
- Final benchmark system: raw; file rank 3/5; original repeat 4; model vendor: DeepSeek

---
## Important interpretive note

This is a **disease-state comparison** (psoriatic lesional skin vs normal control skin). All log2FC values are therefore “up” or “down” in lesional skin relative to control. There are no hazard ratios, so no prognostic statements are made. The statistical signals are extremely strong at the gene level, but statistical confidence does not by itself establish biological causation.

---

# 1. Overall biological interpretation

The lesional psoriasis transcriptome is dominated by a coordinated **keratinocyte-centered inflammatory and regenerative program**. The strongest signal is not a single gene but a set of interconnected modules:

- **IL-36 and IL-20 family cytokine amplification** (IL36A, IL36G, IL19, IL20, IL26) with the endogenous antagonist IL36RN also induced, suggesting active pathway engagement with attempted feedback regulation.
- **S100 alarmins and antimicrobial peptides** (S100A7, S100A7A, S100A8, S100A12, DEFB4A/B, DEFB103A/B, PI3), pointing to innate immune activation, neutrophil recruitment, and skin barrier defense.
- **Aberrant keratinocyte differentiation and cornified-envelope remodeling** (SPRR2 family, SPRR3, LCE3A/D, KRT6A, GJB2/GJB6), reflecting the regenerative/hyperproliferative keratinocyte phenotype.
- **Cell-cycle and metabolic reprogramming** (CCNE1, RRM2, CDK5R1, AKR1B10/15, KYNU, FABP5, SLC6A14), likely supporting keratinocyte proliferation and altered lipid/amino-acid metabolism.
- **Immune recruitment, T-cell activation, and checkpoint induction** (CXCL13, CXCR2, PRKCQ, CD274, ADAP2, HRH2), implicating both innate and adaptive immune contributions.

Importantly, the dataset also shows **concurrent upregulation of negative regulators** such as IL36RN, TNIP3, and ZC3H12A. This suggests that inflammatory signaling is accompanied by induced inhibitory mechanisms, but in lesional skin the overall balance is clearly toward inflammation and tissue remodeling.

The downregulated genes are fewer and less clearly organized. Among annotated genes, **BTC** (betacellulin, an EGFR ligand), **CYP2W1**, **UGT3A2**, and **SAPCD1** are notable. This downregulated set is too small to define a major program, but it is consistent with a shift away from a quiescent, xenobiotic-metabolizing, homeostatic keratinocyte state.

---

# 2. Core biological programs

## Program 1: IL-36 and IL-20 family cytokine amplification

- **Direction:** Up in lesional skin.
- **Supporting genes:** IL36A, IL36G, IL36RN, IL19, IL20, IL26; related downstream/regulatory genes include IRAK2 and ZC3H12A.
- **Pathway annotation:**
  - GO: “positive regulation of inflammatory response”
  - Reactome: “Interleukin-1 family signaling”
  - KEGG: “Cytokine-cytokine receptor interaction”
  - Hallmark: “IL6_JAK_STAT3_SIGNALING” relevant to the IL-20 family/STAT3 arm
- **Why these genes indicate this program:** IL36A and IL36G are IL-1-family cytokines strongly implicated in skin inflammation; IL19, IL20, and IL26 are IL-10-family cytokines that signal through STAT3 and affect keratinocyte proliferation and inflammation. IL36RN encodes the IL-36 receptor antagonist, so its upregulation likely represents an induced feedback brake rather than simple pathway activation.
- **Strength and limitations:** Very strong statistical support from multiple cytokine genes with extremely small FDRs. However, bulk tissue cannot identify which cell types produce these cytokines, and expression alone does not prove a causal hierarchy.

---

## Program 2: S100 alarmin and antimicrobial peptide response

- **Direction:** Up in lesional skin.
- **Supporting genes:** S100A7, S100A7A, S100A8, S100A12, DEFB4A, DEFB4B, DEFB103A, DEFB103B, PI3, TCN1.
- **Pathway annotation:**
  - GO: “antimicrobial humoral immune response mediated by antimicrobial peptide”
  - GO: “defense response to bacterium”
  - Reactome: “Antimicrobial peptides”
- **Why these genes indicate this program:** S100 proteins are alarmins and damage-associated molecular patterns; S100A8 and S100A12 are potent neutrophil chemoattractants. Beta-defensins are antimicrobial peptides and chemoattractants for immune cells. PI3/elafin is a protease inhibitor with antimicrobial properties. Together, they form a strong innate antimicrobial/alarmin response characteristic of psoriatic plaques.
- **Strength and limitations:** Highly significant, reproducible-looking signals. However, many of these genes belong to duplicated or highly homologous families, so the number of independent signals is lower than the gene count suggests. Some genes, especially TCN1 and S100A8/A12, may derive largely from infiltrating neutrophils rather than keratinocytes.

---

## Program 3: Aberrant keratinocyte differentiation and cornified-envelope remodeling

- **Direction:** Up in lesional skin.
- **Supporting genes:** SPRR2A, SPRR2B, SPRR2D, SPRR2E, SPRR2F, SPRR2G, SPRR3, LCE3A, LCE3D, KRT6A, GJB2, GJB6, SERPINB3, SERPINB4, SERPINB13, SERPINB11, KLK13, TMPRSS11D, PRSS27.
- **Pathway annotation:**
  - GO: “keratinization”
  - GO: “cornified envelope”
  - Reactome: “Formation of the cornified envelope”
- **Why these genes indicate this program:** Psoriasis is characterized by a regenerative epidermal differentiation program. SPRRs and LCEs are structural components of the cornified envelope; KRT6A is a hyperproliferative/wound-associated keratin; GJB2/GJB6 encode gap-junction proteins dysregulated in activated keratinocytes; serine proteases and serpins reflect altered desquamation and protease–antiprotease balance.
- **Strength and limitations:** Strong and tissue-specific support from many structural genes. However, whether this differentiation abnormality is a cause or a consequence of the inflammatory response cannot be determined from expression data alone.

---

## Program 4: Keratinocyte proliferation and metabolic reprogramming

- **Direction:** Up in lesional skin, with concurrent downregulation of some homeostatic/xenobiotic metabolism genes.
- **Supporting genes:** RRM2, CCNE1, CDK5R1, AKR1B10, AKR1B15, KYNU, FABP5, SLC6A14, GDA, TPBG.
- **Pathway annotation:**
  - Hallmark: “E2F_TARGETS”
  - GO: “keratinocyte proliferation”
  - Reactome: “Cell Cycle”
  - KEGG: “Cell cycle”
- **Why these genes indicate this program:** CCNE1 and RRM2 drive cell-cycle progression and DNA synthesis; CDK5R1 is an activator of CDK5, which can regulate keratinocyte behavior. AKR1B10/15, KYNU, FABP5, and SLC6A14 support metabolic needs for proliferating cells, including lipid metabolism, amino-acid transport, and redox balance. Downregulation of CYP2W1 and UGT3A2 is consistent with loss of a more quiescent metabolic state.
- **Strength and limitations:** Direct cell-cycle genes plus metabolic-support genes are strong, but some metabolic genes could also be expressed by infiltrating immune cells. Proliferation is inferred from RNA markers, not directly measured.

---

## Program 5: Immune recruitment, T-cell activation, and checkpoint induction

- **Direction:** Up in lesional skin.
- **Supporting genes:** CXCL13, CXCR2, ADAP2, HRH2, PRKCQ, CD274, PLA2G4D, PLA2G4E, HPSE.
- **Pathway annotation:**
  - GO: “leukocyte chemotaxis”
  - GO: “T cell activation”
  - Reactome: “Chemokine receptors bind chemokines”
  - KEGG: “Chemokine signaling pathway”
  - Hallmark: “INFLAMMATORY_RESPONSE”
- **Why these genes indicate this program:** CXCL13 is a B-cell/T-follicular-helper-associated chemokine; CXCR2 is a neutrophil/myeloid chemokine receptor; PRKCQ encodes PKCθ, a critical T-cell activation kinase; CD274/PD-L1 is an immune checkpoint ligand; PLA2G4D/E generate lipid mediators that can promote inflammation; HPSE remodels the extracellular matrix and supports leukocyte trafficking.
- **Strength and limitations:** Multiple immune-related genes support a mixed innate and adaptive immune infiltrate. However, bulk tissue does not resolve which cell types express these genes, and the relationships among them are likely indirect.

---

# 3. Key genes and interaction modules

Abbreviations used for evidence types:  
**D** = direct evidence from the input dataset; **P** = pathway/ontology evidence; **I** = protein interaction/regulatory evidence; **A** = disease-association literature; **E** = expression/tissue-specific evidence; **G** = genetic/clinical evidence; **T** = drug/therapeutic evidence.

No direct physical interaction is inferred solely from co-expression or pathway co-membership unless explicitly stated.

| Key module/genes | Direction | Potential role | Relationship nature |
|---|---|---|---|
| **IL36A, IL36G, IL36RN, IL19, IL20, IL26** | All up | Cytokine amplification and partial feedback inhibition | Pathway co-membership; IL36RN competitively inhibits the IL-36 receptor; IL19/20/26 share IL-20 receptor subunits. No direct ligand–antagonist physical interaction is implied. Evidence: D, P, A, G. |
| **S100A7, S100A7A, S100A8, S100A12** | All up | Alarmins, antimicrobial defense, neutrophil chemoattraction | Co-expression in lesional tissue; S100A8 can heterodimerize with S100A9, but S100A9 was not measured; direct interactions among all listed proteins are not established. Evidence: D, P, A, E. |
| **DEFB4A, DEFB4B, DEFB103A, DEFB103B, PI3, TCN1** | All up | Antimicrobial peptides and neutrophil-related defense proteins | Co-regulated antimicrobial response. DEFB4A/B and DEFB103A/B are highly similar duplicated loci, so they should not be treated as fully independent signals. Evidence: D, P, A, E. |
| **SPRR2A/B/D/E/F/G, SPRR3, LCE3A/D, KRT6A, GJB2/GJB6** | All up | Cornified-envelope remodeling, hyperproliferative keratins, gap-junction changes | Pathway co-membership in keratinization; SPRR and LCE proteins are crosslinked substrates in the cornified envelope. Direct protein interactions are not demonstrated by this dataset. Evidence: D, P, E, A. |
| **SERPINB3, SERPINB4, SERPINB13, SERPINB11, KLK13, TMPRSS11D, PRSS27, PI3** | All up | Protease–antiprotease imbalance and barrier/desquamation remodeling | Putative protease–inhibitor relationships, but direct physical pairings between specific serpins and kallikreins are not shown here. Evidence: D, P, A. |
| **RRM2, CCNE1, CDK5R1, AKR1B10, AKR1B15, KYNU, FABP5, SLC6A14, GDA** | All up | Cell-cycle progression and metabolic support for proliferation | Co-expression and pathway co-membership in cell-cycle and metabolic networks; no direct physical interaction is inferred. Evidence: D, P, A. |
| **CXCL13, CXCR2, PRKCQ, CD274, HRH2, ADAP2** | All up | Immune recruitment, T-cell activation, checkpoint signaling | Co-present in inflamed tissue but likely expressed by different cell types. CXCL13 does not signal through CXCR2, so their relationship is indirect/network-level, not direct ligand–receptor. Evidence: D, P, A, E. |
| **IL36RN, TNIP3, ZC3H12A** | All up | Negative regulators / feedback control of inflammation | Regulatory interactions: IL36RN blocks IL-36R signaling; TNIP3 inhibits NF-κB signaling; ZC3H12A degrades inflammatory mRNAs. These are regulatory relationships, not necessarily direct physical binding. Evidence: D, I, A, G. |
| **PLA2G4D, PLA2G4E, HPSE, WNT5A** | All up | Eicosanoid generation, matrix remodeling, noncanonical Wnt signaling | Distinct signaling pathways coordinately upregulated in lesional skin; relationship is indirect/putative. Evidence: D, P, A. |
| **BTC** | Down | Loss of homeostatic EGFR ligand expression | Single-gene finding; insufficient evidence for a broader module. Potential biomarker or differentiation-state marker. Evidence: D, A, E. |

---

# 4. Validation priorities

## 1. Mechanistic hypothesis: IL-36/IL-20 cytokines drive the feed-forward inflammatory program

- **Why prioritized:** IL36A, IL36G, IL19, IL20, and IL26 are among the strongest upregulated genes in the dataset; they sit upstream of many downsteam keratinocyte and immune genes.
- **Current dataset evidence:** Strong upregulation of multiple IL-36 and IL-20 family cytokines plus induction of the antagonist IL36RN.
- **External evidence:** Human genetics link IL36RN loss-of-function mutations to pustular skin disease; IL-36 and IL-20 family cytokines are known to induce keratinocyte chemokines, antimicrobial peptides, and proliferation.
- **Next step:** Block IL-36R and/or IL-20 receptor signaling in psoriasiform mouse models or human skin organotypic cultures and measure S100/defensin expression, keratinocyte proliferation, and immune infiltration.
- **Status:** **Supported hypothesis**, not established evidence.

---

## 2. Interaction/network hypothesis: keratinocyte alarmins recruit and activate immune cells

- **Why prioritized:** The simultaneous upregulation of S100 alarmins, beta-defensins, CXCR2, and CXCL13 suggests a keratinocyte–immune amplification loop, but bulk RNA cannot prove directionality.
- **Current dataset evidence:** S100A7/A8/A12, DEFB4A/B, DEFB103A/B, CXCR2, and CXCL13 are all strongly upregulated.
- **External evidence:** S100 proteins and beta-defensins have chemoattractant activity for myeloid cells, and psoriatic lesions contain neutrophil microabscesses and T-cell infiltrates.
- **Next step:** Use spatial transcriptomics or single-cell RNA-seq to localize ligand and receptor expression; then test keratinocyte-conditioned medium from IL-36-stimulated keratinocytes on neutrophil/T-cell migration in vitro.
- **Status:** **Exploratory hypothesis.**

---

## 3. Biomarker candidates: S100A12, S100A8, DEFB4A, PI3, and BTC

- **Why prioritized:** These genes have very large effect sizes and may be useful tissue or blood biomarkers for disease activity and treatment response.
- **Current dataset evidence:** Strong, highly significant upregulation of S100A12, S100A8, DEFB4A, and PI3; BTC is consistently downregulated.
- **External evidence:** S100A8/A9 (calprotectin) is already used as an inflammatory biomarker in several diseases; beta-defensins are increased in psoriatic skin.
- **Next step:** Validate in an independent psoriasis cohort by qPCR and protein assays; correlate with PASI and with response to anti-IL-17/IL-23 therapy.
- **Status:** **Supported hypothesis** as tissue biomarker candidates; clinical utility remains **exploratory**.

---

## 4. Confounding / composition check: cell-type origin of the signal

- **Why prioritized:** Psoriatic lesions contain increased neutrophils, T cells, dendritic cells, and altered keratinocyte composition. Many top genes may come from immune infiltrate rather than keratinocytes.
- **Current dataset evidence:** S100A12, S100A8, TCN1, CXCR2, PRKCQ, CXCL13, and CD274 are plausibly immune-cell-associated.
- **External evidence:** Histology of psoriasis shows epidermal neutrophil collections and T-cell infiltration.
- **Next step:** Perform single-cell RNA-seq, spatial transcriptomics, or cell sorting to determine which cell types express the defining genes. Deconvolution of bulk RNA could also help.
- **Status:** **Established methodological concern**, not a biological conclusion.

---

## 5. Therapeutic target evaluation: PKCθ/PRKCQ in pathogenic T cells

- **Why prioritized:** PRKCQ is strongly upregulated and encodes an intracellular kinase required for T-cell activation, making it a targetable node in the adaptive immune arm.
- **Current dataset evidence:** PRKCQ is upregulated in lesional skin.
- **External evidence:** PKCθ is required for T-cell receptor-driven activation; PKC inhibitors have been explored in psoriasis. However, the existence of a drug or target does not itself prove therapeutic efficacy.
- **Next step:** Use selective PKCθ inhibition or genetic silencing in patient-derived T cells and skin explant assays; measure IL-17/IL-22 production and downstream keratinocyte responses.
- **Status:** **Supported hypothesis** as a therapeutic rationale, **exploratory** for clinical efficacy.

---

# 5. Evidence grounding

The interpretation integrates several evidence types:

- **Direct dataset evidence:** log2FC, P values, and FDRs from the input table.
- **Pathway/ontology evidence:** GO, Reactome, KEGG, and Hallmark annotations place the genes into known biological processes.
- **Protein interaction/regulatory evidence:** e.g., IL36RN antagonizes IL-36 receptor signaling; ZC3H12A degrades inflammatory mRNAs; TNIP3 inhibits NF-κB.
- **Disease-association literature:** many of these modules are well described in psoriasis and other inflammatory skin diseases.
- **Expression/tissue-specific evidence:** several genes, such as KRT6A, SPRRs, and LCEs, are known keratinocyte differentiation markers.
- **Genetic/clinical evidence:** IL36RN genetics link IL-36 signaling to pustular skin diseases; S100A8/A9 is used clinically as calprotectin.
- **Drug/therapeutic evidence:** anti-IL-36R and PKC inhibitors have been studied in inflammatory skin disease, but this does not by itself prove efficacy in the current context.

These evidence sources are not fully independent. Pathway annotations are derived from the same gene lists, and literature evidence may be based on similar bulk-tissue transcriptomic studies. Duplicated gene families, especially S100A7/A7A and DEFB4A/B, further reduce the effective number of independent observations. Genetic evidence for IL36RN is more independent because it comes from heritable loss-of-function disease, not from expression profiling.

---

# 6. Limitations and alternative explanations

## 1. Cell-composition differences

Psoriatic lesions are not simply “normal skin with different gene expression”; they contain more neutrophils, T cells, dendritic cells, and hyperproliferative keratinocytes. Bulk RNA-seq signals may reflect changes in cell proportions rather than intrinsic transcriptional changes in a single cell type. This is especially important for S100A8/A12, TCN1, CXCR2, PRKCQ, and CD274.

**How to distinguish:** single-cell RNA-seq, spatial transcriptomics, immunohistochemistry, or cell sorting followed by RNA-seq.

---

## 2. Disease severity and treatment exposure

No clinical metadata are provided. Genes strongly affected by prior treatment — including topical steroids, biologics, or phototherapy — could be over- or under-represented. The comparison is lesional vs normal control skin, so treatment effects and disease severity are uncontrolled.

**How to distinguish:** collect detailed clinical metadata, including PASI, treatment status, and washout periods; validate in independent cohorts.

---

## 3. Duplicate/homologous gene families and mapping ambiguity

Some of the strongest signals come from duplicated, highly homologous genes: S100A7/S100A7A, DEFB4A/DEFB4B, DEFB103A/DEFB103B, and closely related SPRR2 genes. Short-read alignment may not fully resolve these genes, and multiple significant “genes” may reflect a smaller number of true biological loci.

**How to distinguish:** use long-read RNA-seq, genomic alignment-aware quantification, or locus-specific PCR.

---

## 4. Broad or nonspecific pathway enrichment

Many of the identified genes are common downstream targets of IL-17, IL-22, IL-36, and TNF. The five programs may therefore not be biologically independent; they may all reflect one shared upstream inflammatory cascade. The apparent coherence could be overinterpreted if the analysis treats co-regulated genes as independent pathway evidence.

**How to distinguish:** perturb specific upstream pathways and measure the downstream modules; use network or causal inference approaches rather than simple overlap.

---

## 5. Association-versus-causation ambiguity

Differential expression establishes association, not causality. The upregulation of negative regulators such as IL36RN, TNIP3, and ZC3H12A could mean the tissue is attempting to suppress inflammation, or it could simply reflect activation of the same inflammatory pathways. Similarly, downregulation of BTC may be a consequence, not a cause, of the altered keratinocyte state.

**How to distinguish:** functional perturbation studies, genetic models, and time-course experiments that separate initiating events from secondary responses.

---

# Final conclusion

The current transcriptomic data provide strong statistical evidence that psoriatic lesional skin is characterized by coordinated upregulation of IL-36/IL-20 cytokines, S100/defensin alarmins, cornified-envelope remodeling genes, cell-cycle/metabolic genes, and immune recruitment/T-cell activation genes. The interpretation is biologically coherent and consistent with established psoriasis biology, but causal hierarchy, cell-type origin, treatment effects, and therapeutic implications require further validation.
